United Therapeutics (UTHR) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

United Therapeutics Revenue Highlights

Latest Revenue (Y)

$2.88B

Latest Revenue (Q)

$748.90M

Main Segment (Y)

Tyvaso

Main Geography (Y)

UNITED STATES

United Therapeutics Revenue by Period

United Therapeutics Revenue by Year

Date	Revenue	Change
2024-12-31	$2.88B	23.63%
2023-12-31	$2.33B	20.20%
2022-12-31	$1.94B	14.88%
2021-12-31	$1.69B	13.63%
2020-12-31	$1.48B	2.38%
2019-12-31	$1.45B	-11.00%
2018-12-31	$1.63B	-5.65%
2017-12-31	$1.73B	7.91%
2016-12-31	$1.60B	9.08%
2015-12-31	$1.47B	13.76%
2014-12-31	$1.29B	15.36%
2013-12-31	$1.12B	21.93%
2012-12-31	$916.08M	23.26%
2011-12-31	$743.18M	23.08%
2010-12-31	$603.83M	63.26%
2009-12-31	$369.85M	31.39%
2008-12-31	$281.50M	33.45%
2007-12-31	$210.94M	32.14%
2006-12-31	$159.63M	37.71%
2005-12-31	$115.92M	57.51%
2004-12-31	$73.59M	37.96%
2003-12-31	$53.34M	77.09%
2002-12-31	$30.12M	425.50%
2001-12-31	$5.73M	179.70%
2000-12-31	$2.05M	412.31%
1999-12-31	$400.00K	300.00%
1998-12-31	$100.00K	-

United Therapeutics generated $2.88B in revenue during NA 2024, up 23.63% compared to the previous quarter, and up 198.61% compared to the same period a year ago.

United Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$748.90M	4.76%
2024-06-30	$714.90M	5.49%
2024-03-31	$677.70M	10.25%
2023-12-31	$614.70M	0.87%
2023-09-30	$609.40M	2.16%
2023-06-30	$596.50M	17.68%
2023-03-31	$506.90M	3.13%
2022-12-31	$491.50M	-4.75%
2022-09-30	$516.00M	10.52%
2022-06-30	$466.90M	1.08%
2022-03-31	$461.90M	11.25%
2021-12-31	$415.20M	-6.63%
2021-09-30	$444.70M	-0.40%
2021-06-30	$446.50M	17.78%
2021-03-31	$379.10M	-1.51%
2020-12-31	$384.90M	1.26%
2020-09-30	$380.10M	5.00%
2020-06-30	$362.00M	1.60%
2020-03-31	$356.30M	14.53%
2019-12-31	$311.10M	-22.52%
2019-09-30	$401.50M	7.47%
2019-06-30	$373.60M	3.03%
2019-03-31	$362.60M	-4.93%
2018-12-31	$381.40M	-7.58%
2018-09-30	$412.70M	-7.15%
2018-06-30	$444.50M	14.21%
2018-03-31	$389.20M	-16.25%
2017-12-31	$464.70M	4.31%
2017-09-30	$445.50M	0.20%
2017-06-30	$444.60M	20.00%
2017-03-31	$370.50M	-9.41%
2016-12-31	$409.00M	0.20%
2016-09-30	$408.20M	-1.07%
2016-06-30	$412.60M	11.82%
2016-03-31	$369.00M	-8.86%
2015-12-31	$404.88M	4.83%
2015-09-30	$386.22M	11.25%
2015-06-30	$347.16M	6.00%
2015-03-31	$327.50M	-5.44%
2014-12-31	$346.36M	4.97%
2014-09-30	$329.95M	2.21%
2014-06-30	$322.80M	11.54%
2014-03-31	$289.40M	0.13%
2013-12-31	$289.02M	-4.37%
2013-09-30	$302.23M	7.70%
2013-06-30	$280.61M	14.47%
2013-03-31	$245.14M	0.54%
2012-12-31	$243.82M	0.56%
2012-09-30	$242.47M	7.49%
2012-06-30	$225.58M	10.46%
2012-03-31	$204.21M	4.63%
2011-12-31	$195.18M	-3.25%
2011-09-30	$201.74M	9.79%
2011-06-30	$183.75M	10.95%
2011-03-31	$165.62M	-0.52%
2010-12-31	$166.48M	-2.64%
2010-09-30	$170.98M	24.36%
2010-06-30	$137.49M	6.68%
2010-03-31	$128.88M	18.32%
2009-12-31	$108.92M	12.04%
2009-09-30	$97.22M	15.76%
2009-06-30	$83.98M	5.33%
2009-03-31	$79.73M	5.10%
2008-12-31	$75.86M	1.11%
2008-09-30	$75.03M	9.45%
2008-06-30	$68.56M	10.49%
2008-03-31	$62.05M	3.59%
2007-12-31	$59.90M	-

United Therapeutics generated $748.90M in revenue during Q3 2024, up 4.76% compared to the previous quarter, and up 125.55% compared to the same period a year ago.

United Therapeutics Revenue Breakdown

United Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Tyvaso	$1.62B	$1.23B	$873.00M	$607.50M	-
Remodulin	$538.10M	$494.80M	$500.20M	$513.70M	$516.70M
Product and Service, Other	$22.10M	$11.80M	$13.80M	-	-
Orenitram	$434.30M	$359.40M	$325.10M	$306.10M	$293.10M
Adcirca	$23.80M	$28.90M	$55.90M	$67.30M	-
Unituxin	$238.70M	$198.90M	$182.90M	$202.30M	$122.90M

United Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Tyvaso (56.31%), Remodulin (18.70%), Orenitram (15.09%), Unituxin (8.30%), Adcirca (0.83%), and Product and Service, Other (0.77%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
Remodulin	$134.50M	$128.30M	$147.30M	$128.00M	$115.10M	$131.10M	$127.20M	$121.40M	$122.50M	$114.00M	$132.00M	$131.70M	$118.30M	$125.40M	$139.80M	$130.20M	$127.90M	$124.50M	$119.00M	$145.30M
Product and Service, Other	$5.50M	$5.50M	$4.90M	$6.20M	$3.90M	$1.90M	$3.50M	$2.50M	$3.80M	-	-	-	-	-	-	-	-	-	-	-
Orenitram	$107.80M	$113.20M	$107.10M	$106.20M	$84.10M	$92.00M	$95.10M	$88.20M	$75.80M	$87.50M	$79.00M	$82.80M	$72.30M	$85.20M	$76.20M	$72.40M	$74.00M	$74.70M	$75.40M	$69.00M
Adcirca	$4.70M	$7.00M	$5.70M	$6.40M	$6.80M	$7.30M	$7.50M	$7.30M	$10.40M	$10.70M	$10.40M	$9.80M	$8.10M	$14.60M	$23.60M	$9.60M	$21.60M	$13.80M	$19.40M	$12.50M
Unituxin	$67.50M	$61.10M	$51.70M	$58.40M	$54.20M	$51.30M	$44.30M	$49.10M	$36.70M	$46.10M	$44.50M	$55.60M	$50.00M	$55.30M	$53.10M	$43.90M	$29.70M	$37.60M	$29.00M	$26.60M
Tyvaso	$415.90M	$433.80M	$398.20M	$372.50M	$676.40M	$318.90M	$238.40M	$242.30M	$257.70M	$201.00M	$172.00M	$166.50M	$164.20M	$153.80M	$123.00M	$129.50M	$119.20M	$102.90M	-	-
Product	-	-	-	-	-	-	-	-	-	$516.00M	$466.90M	$451.90M	-	-	-	-	-	-	-	-

United Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Tyvaso (56.52%), Remodulin (18.28%), Orenitram (14.65%), Unituxin (9.17%), Product and Service, Other (0.75%), and Adcirca (0.64%).

United Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Non-US	$137.70M	$125.30M	$122.20M	$121.30M	-
UNITED STATES	$2.74B	$2.20B	$1.81B	$1.56B	$1.41B
European Union And Others	-	-	-	-	$71.20M

United Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (95.21%), and Non-US (4.79%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19
Non-US	$30.20M	$31.60M	$39.70M	$36.20M	$28.80M	$24.80M	$34.50M	$37.20M	$27.80M	$15.80M	$26.50M	$52.10M	-	-	-	-	-	-	-	-
UNITED STATES	$705.70M	$717.30M	$675.20M	$641.50M	$585.90M	$584.60M	$562.00M	$469.70M	$463.70M	$500.20M	$440.40M	$409.80M	$386.10M	$412.10M	$411.70M	$354.30M	$369.00M	$350.80M	-	-
European Union And Others	-	-	-	-	-	-	-	-	-	-	-	-	-	$32.60M	$34.80M	$24.80M	$11.10M	$11.20M	$29.60M	$16.30M
U	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$326.70M	$294.80M

United Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (95.90%), and Non-US (4.10%).

United Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
INCY	Incyte	$4.24B	$962.99M
UTHR	United Therapeutics	$2.88B	$748.90M
BGNE	BeiGene	$2.46B	$929.17M
ALNY	Alnylam Pharmaceuticals	$2.25B	$420.15M
APLS	Apellis Pharmaceuticals	$709.95M	$176.57M
RARE	Ultragenyx Pharmaceutical	$560.23M	$147.03M
BPMC	Blueprint Medicines	$508.82M	$128.18M
KNSA	Kiniksa Pharmaceuticals	$423.24M	$112.21M
MNKD	MannKind	$285.50M	$19.73M
LEGN	Legend Biotech	$285.14M	$93.99M
ASND	Ascendis Pharma	$266.72M	$95.89M
DAWN	Day One Biopharmaceuticals	$131.16M	$20.07M
AKRO	Akero Therapeutics	-	-
VTYX	Ventyx Biosciences	-	-
PCVX	Vaxcyte	-	-
NUVL	Nuvalent	-	-
REPL	Replimune Group	-	-
LRMR	Larimar Therapeutics	-	-

UTHR Revenue FAQ

What is United Therapeutics’s yearly revenue?

United Therapeutics's yearly revenue for 2024 was $2.88B, representing an increase of 23.63% compared to 2023. The company's yearly revenue for 2023 was $2.33B, representing an increase of 20.20% compared to 2022. UTHR's yearly revenue for 2022 was $1.94B, representing an increase of 14.88% compared to 2021.

What is United Therapeutics’s quarterly revenue?

United Therapeutics's quarterly revenue for Q3 2024 was $748.9M, a 4.76% increase from the previous quarter (Q2 2024), and a 22.89% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $714.9M, a 5.49% increase from the previous quarter (Q1 2024), and a 19.85% increase year-over-year (Q2 2023). UTHR's quarterly revenue for Q1 2024 was $677.7M, a 10.25% increase from the previous quarter (Q4 2023), and a 33.70% increase year-over-year (Q1 2023).

What is United Therapeutics’s revenue growth rate?

United Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 48.60%, and for the last 5 years (2020-2024) was 93.99%.

What are United Therapeutics’s revenue streams?

United Therapeutics's revenue streams in c 24 are Tyvaso, Remodulin, Product and Service, Other, Orenitram, Adcirca, and Unituxin. Tyvaso generated $1.62B in revenue, accounting 56.31% of the company's total revenue, up 31.34% year-over-year. Remodulin generated $538.1M in revenue, accounting 18.70% of the company's total revenue, up 8.75% year-over-year. Product and Service, Other generated $22.1M in revenue, accounting 0.77% of the company's total revenue, up 87.29% year-over-year. Orenitram generated $434.3M in revenue, accounting 15.09% of the company's total revenue, up 20.84% year-over-year. Adcirca generated $23.8M in revenue, accounting 0.83% of the company's total revenue, down -17.65% year-over-year. Unituxin generated $238.7M in revenue, accounting 8.30% of the company's total revenue, up 20.01% year-over-year.

What is United Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of United Therapeutics was Tyvaso. This segment made a revenue of $1.62B, representing 56.31% of the company's total revenue.